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Insulin use is associated with poor limb salvage
and survival in diabetic patients with chronic limb
ischemia
Hasan H. Dosluoglu, MD,a,b Purandath Lall, MD,a,b Nader D. Nader, MD, PhD,b,c
Linda M. Harris, MD,b and Maciej L. Dryjski, MD,b Buffalo, NY
Objective: The goal was to compare the outcomes in patients with disabling claudication (DC) or critical limb ischemia
(CLI) to determine if diabetics (DM) have poorer patency, limb salvage (LS), and survival rates than nondiabetic patients
and if the diabetic regimen affects these outcomes.
Methods: All patients who presented with DC or CLI between June 2001 and September 2008 were included. Non-DM
patients were compared with those with DM who are currently managed by diet only or oral medications (D-OM), oral
medications plus insulin (OMINS), or insulin alone (INS).
Results: Of the 746 patients (886 limbs), there were 406 patients (464 limbs) in non-DM, 96 patients (135 limbs) in
D-OM, 98 patients (118 limbs) in OMINS, and 146 patients (185 limbs) in INS groups. There were more patients with
coronary artery disease, hypertension, and renal insufficiency in the DM group than non-DM, with the INS group having
the highest incidence of renal insufficiency/dialysis (46%/20%). Gangrene and foot sepsis were significantly more
frequent in patients in OMINS (45%/3%) and INS (50%/6%) than non-DM (15%/0.2%) and D-OM groups (25%/1%;
P < .001). More patients in the INS group (14%) and OMINS (9%) had primary amputation than non-DM (4%) and
D-OM (4%; P < .01). Mean follow-up was 26.3  20.7 months. Overall survival following revascularization was similar
in D-OM and non-DM andOMINS and INS, the latter being significantly worse (P< .001). The LS rate in D-OM and
non-DM was also identical, whereas OM-INS and INS had significantly worse LS, with OM-INS marginally better than
INS (P  .094). Primary patency (PP) was worse in endovascular-treated patients on insulin than non-DM and D-OM
patients (P < .001), whereas PP was similar between groups in open-treated patients. Multivariate analysis showed that
coronary artery disease, renal insufficiency, chronic obstructive pulmonary disease, indication for intervention, insulin
use, nonambulatory status, and statin drug non-use were independently associated with decreased survival, whereas
insulin use, presence of gangrene, need for infrapopliteal interventions, and nonambulatory status were independently
associated with limb loss. TransAtlantic Inter-Society Consensus (TASC) classification of the treated lesions being C or
D, infrapopliteal interventions, and indication of intervention (DC vs CLI) were independently associated with primary
patency, whereas insulin use was not.
Conclusions: Diabetic patients who present with limb ischemia can be subdivided into three distinct subgroups based on
their diabetic regimen. The survival and LS rates of those controlled with diet or OM are nearly identical to nondiabetics,
both of which are significantly better than OMINS or INS. The PP rate in endovascular-treated patients is worse in
patients who are on insulin. Being on insulin is independently associated with decreased survival and limb loss but not PP.
(J Vasc Surg 2010;51:1178-89.)The incidence of diabetes mellitus (DM) is on the rise,
and it is estimated that it will increase by 200% between
2005 and 2050.1 Since approximately one-quarter of pa-
tients with peripheral arterial disease (PAD) have been
estimated to have diabetes,2 an increasingly larger propor-
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1178tion of patients with PAD who undergo revascularization
procedures will be diabetic. With the increased use of
endovascular interventions for patients with limb ischemia,
an endovascular-first approach has been adopted for pa-
tients with DM in many specialized centers, including our
own.3-6
The efficacy of open revascularization in diabetic patients
with critical limb ischemia (CLI) has been largely ac-
cepted.7-10 Although there have been large studies which
reported similar patency,9-11 limb salvage,3,7,12-14 and sur-
vival rates3,10,14 in patients with or without DM following
open or endovascular revascularizations, poorer patency,11-15
limb salvage,9,11,17 and survival rates13,17 have also been re-
ported for diabetics. Although patients on insulin were not
analyzed separately in most of these studies, its use has
been associated with poorer patency,18 limb salvage,9,11
and survival9 rates.
The use of insulin has been associated with increasedcardiovascular morbidity and mortality;19,20 however,
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the severity of diabetes.21,22 Few reports on open or endo-
vascular interventions in diabetics have differentiated those
requiring insulin for diabetes control and those who did
not,9,11,18 and the conflicting reports may stem from the
fact that the patient populations may not be similar in terms
of severity of diabetes. The goal of our study was to
compare the outcomes in patients with disabling claudica-
tion (DC) or CLI to determine if diabetics (DM) have
poorer patency, limb salvage (LS), and survival rates than
nondiabetic patients and if diabetic regimen affects these
outcomes.
MATERIAL AND METHODS
Consecutive patients who presented to the Veterans’
Administration Western New York Healthcare System
(Buffalo, NY) between June 1, 2001 and September 30,
2008 with chronic limb ischemia (Rutherford category
3-6)23 and underwent endovascular, open bypass, hybrid
revascularization procedures, or primary amputations were
prospectively entered into our database. Patients were di-
vided into those with diabetes (DM group) and those
without (non-DM group), and the DM group was sub-
grouped into those whose diabetes was managed by diet or
oral medications (D-OM group), a combination of oral
medications and insulin (OMINS group), or by insulin
alone (INS group). Demographics, comorbidities, medica-
tion usage, clinical presentation, preoperative functional
status, noninvasive arterial studies, other imaging studies,
TransAtlantic Inter-Society Consensus (TASC) classifica-
tion,24,25 details of the procedures performed, the most
distal level of intervention, postoperative course, length of
stay (LOS), follow-up arterial studies, and status of limbs
on last follow-up were recorded.
CLI was defined as the presence of ischemic rest pain
for more than two weeks or ischemic tissue loss associated
with an absolute ankle pressure less than 50 mmHg, or toe
pressure less than 30 mm Hg. Patients with acute limb
ischemia, those with ulcers, and those who had normal
arterial circulation with palpable pedal pulses and normal
pressures were excluded. Coronary artery disease was de-
fined as documented angina pectoris, myocardial infarc-
tion, congestive heart failure, or history of coronary artery
revascularization. Renal insufficiency was defined as a se-
rum creatinine level higher than 1.5 mg/dL. Cerebrovas-
cular disease was defined as a history of stroke, transient
ischemic attack, carotid artery revascularization, or a known
50% carotid artery stenosis. Hypertension was defined as
documented systolic blood pressure of 150 mm Hg,
diastolic blood pressure of90 mmHg, or pharmacologic
treatment with at least one medication. Hypercholesterol-
emia was defined as fasting cholesterol level200 mg/dL,
low-density lipoprotein level130mg/dL, or triglycerides
200 mg/dL, before starting on lipid-lowering drugs.
DM was defined as fasting plasma glucose 120 mg/dL,
hemoglobin A1c7%, or treatment with hypoglycemic
medications. Amputations were considered major when
performed above the ankle level. The original TASC classi-fication was used until 2007,24 after which TASC II classi-
fication25 was used for iliac and femoropopliteal lesions;
however, the original classification was continued to be
used for infrapopliteal lesions since the TASC II document
did not provide a classification of those lesions.
The decision to proceed with endovascular interven-
tion or open bypass was made by the vascular surgeon,
following the diagnostic angiogram, with increasing use of
endovascular interventions over the study period. Contin-
uous multilevel occlusions, those with bulky common fem-
oral disease, flush superficial femoral artery (SFA) occlu-
sions, and in patients in whom in-line to the foot was not
feasible by endovascular interventions were preferentially
treated by open revascularizations. All endovascular proce-
dures were performed by vascular surgeons in the operating
room using the OEC 9800 system (General Electric Med-
ical Systems, Salt Lake City, UT). Primary stent placement
was used in all iliac lesions. For SFA interventions, TASC A
and B lesions were treated using percutaneous transluminal
angioplasty (PTA), and stents were used for flow-limiting
dissections or residual stenosis or recoil of 30%. Intralu-
minal crossing was intended for all cases. Most occlusions
were crossed using a combination of Glidewire (Terumo,
Somerset, NJ) and Glidecath (4 or 5F; Terumo) or Quick-
Cross catheters (Spectranetics, Colorado Springs, Colo). A
predilation was followed by stent placement in all SFA occlu-
sions (TASC C and D lesions), whereas PTA alone with
provisional stenting was used for popliteal and infrapopliteal
occlusions. Debulking procedures were used in a small num-
ber of patients (Excimer laser atherectomy; Spectranetics;
SilverHawk atherectomy; Foxhollow Inc, Redwood City,
Calif).
Patients typically received 5000 U after sheath place-
ment, and the heparin was not reversed at the end of the
procedure. Clopidogrel bisulfate was started in the recovery
room (300 mg), and was maintained (75 mg daily) for a
minimum of 30 days. Lifelong enteric-coated acetyl sali-
cylic acid (ECASA; 81 mg) was also given.
All patients considered for open infrageniculate bypass
were evaluated preoperatively by duplex for availability and
quality of the greater saphenous veins, with preferential use
of ipsilateral greater saphenous veins (GSV). Contralateral
GSV or arm veins were used before using synthetic grafts,
when ipsilateral GSV was not available or small (3 mm).
Above-the-knee femoropopliteal bypasses (AK-FPB), ex-
tra-anatomic bypasses, or aortobifemoral bypasses were
preferentially performed using polytetrafluororethylene
(PTFE) grafts. Precuffed PTFE grafts were used in patients
undergoing infrageniculate bypasses using PTFE grafts.
Postoperatively, all patients who had AK-FPB were kept on
ECASA, or on clopidogrel when ECASA could not be
used. Therapeutic warfarin (International Normalized Ra-
tio kept between 2.0-3.0) was used for below-the-knee
PTFE grafts.
Technical success was defined as a patent vessel
with 30% residual stenosis. All patients were followed
postoperatively, and at three and six months and every
six months thereafter for ankle-brachial index (ABI) mea-
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Non-DM D-OM OMINS INS
Patients (n  406) (n  96) (n  146) (n  98) P
Age 67.6  10.9 69.6  9.3 71.0  10.3 69.0  10.3 .013a
Coronary artery disease 51% 63% 69% 72% .001b
Hypertension 70% 82% 77% 82% .009c
Cerebrovascular disease 20% 17% 23% 24% .337
Lipid 70% 69% 76% 67% .566
Chronic obstructive occlusive disease 28% 27% 21% 17% .016d
Renal 15% 30% 32% 46% .001e
Dialysis 4% 6% 4% 20% .002f
Active smoker 57% 38% 32% 34% .001g
Beta-blocker 55% 50% 58% 61% .265
Angiotensin-converting enzyme inhibitor 43% 61% 58% 58% .001h
Statin 53% 62% 59% 57% .203
Nonambulatory 20% 14% 30% 40% .001i
Limbs (n  464) (n  119) (n  185) (n  118)
Disabling claudication 42% 41% 17% 7% .001j
Rest pain 25% 10% 5% 7% .001k
Ulcer 17% 25% 30% 29% .001l
Gangrene 15% 25% 45% 50% .001m
Foot sepsis 0.2% 1% 3% 6% .001n
D-OM, Diet-controlled or oral medication-controlled group; INS, insulin-only group; Non-DM, nondiabetic group; OMINS, oral medication plus
insulin-controlled group.
aP value for non-DM vs OMINS groups. P  .05 for all other group comparisons for age.
bNon-DM vs OMINS, P  .003; non-DM vs INS, P  .001.
cNon-DM vs D-OM, P  .003; non-DM vs INS, P  .003.
dNon-DM vs INS, P  .047.
eNon-DM vs D-OM, P  .024; non-DM vs OMINS, P  .001; non-DM vs INS, P  .001; D-OM vs INS, P  .003; OMINS vs INS, P  .085.
fNon-DM vs INS, P  .001; D-OM vs INS, P  .002; OMINS vs INS, P  .002.
gNon-DM vs D-OM, P  .002; non-DM vs OMINS, P  .001; non-DM vs INS, P  .001.
hNon-DM vs D-OM, P  .002; non-DM vs OMINS, P  .013; non-DM vs INS, P  .001.
iNon -DM vs OMINS, P  .068; non-DM vs INS, P  .001; D-OM vs OMINS, P  .013.
jNon-DM vs OMINS, P  .001; non-DM vs INS, P  .001; D-OM vs OMINS, P  .001; D-OM vs INS, P  .001; OMINS vs INS, P  .003.
kNon-DM vs D-OM, P  .001; non-DM vs OMINS, P  .001; non-DM vs INS, P  .001.
lNon-DM vs D-OM, P  .068; non-DM vs OMINS, P  .007; non-DM vs INS, P  .001.
mNon-DM vs D-OM, P  .059; non-DM vs OMINS, P  .001; non-DM vs INS, P  .001; D-OM vs OMINS, P  .001; D-OM vs INS, P  .001.
nNon-DM vs OMINS, P  .007; non-DM vs INS, P  .001; D-OM vs INS, P  .019.
P values for subgroup comparisons are given only if P  .1.Table II. The most distal level of intervention and type of procedures performed in groups based on treated limbs
Non-DM D-OM OMINS INS
(n  445) (n  114) (n  158) (n  107) P
Aortoiliac 40% 25% 17% 7% .001a
Femoropopliteal 40% 50% 50% 43% .03b
Infrapopliteal 20% 25% 33% 50% .001c
Multilevel 28% 27% 36% 41% .005d
(n  464) (n  119) (n  185) (n  118)
Open 29% 29% 19% 25% .133
Endovascular 49% 61% 64% 53% .009e
Hybrid 18% 8% 8% 8% .001f
PA 4% 4% 9% 14% .001g
D-OM, Diet-controlled or oral medication-controlled group; INS, insulin-only group; Non-DM, nondiabetic group; OMINS, oral medication plus
insulin-controlled group; PA, primary amputation.
aNon-DM vs D-OM, P  .003; non-DM vs OMINS, P  .001; non-DM vs INS, P  .001; D-OM vs INS, P  .001; OMINS vs INS, P  .006.
bNon-DM vs D-OM, P  .011; non-DM vs OMINS, P  .008; D-OM vs INS, P  .065; OMINS vs INS, P  .006.
cNon-DM vs OMINS, P  .021; non-DM vs INS, P  .001; D-OM vs INS, P  .001; OMINS vs INS, P  .002.
dNon-DM vs INS, P  .003; D-OM vs OMINS, P  .08; D-OM vs INS, P  .004.
eNon-DM vs D-OM, P  .024; non-DM vs OMINS, P  .005; OMINS vs INS, P  .057.
fNon-DM vs D-OM, P  .007; non-DM vs OMINS, P  .007; non-DM vs INS, P  .001.
gNon-DM vs OMINS, P  .029; non-DM vs INS, P  .001; D-OM vs INS, P  .004.
P values for subgroup comparisons are given only if P  .1.
MI
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We performed repeat angiograms to reassess the adequacy
of pedal flow when wound healing was felt to be inade-
quate, or when duplex suggested restenosis. The loss of
patency was defined as occlusion, 50% restenosis, an
elevated ratio of velocity to the proximal segment being
3:1 by duplex examination, loss of a previously palpable
pulse, or decrease in ABI of 0.2.
Society for Vascular Surgery (SVS) reporting stan-
dards for lower extremity arterial procedures were fol-
lowed.23 Data analysis was performed using SPSS 16.0
software (SPSS Inc., Chicago, IL). Kaplan-Meier analysis
and log-rank test were used to compare groups for
primary patency (PP), assisted-primary patency (APP),
SP, limb salvage (LS), and overall survival, on an intent-
to-treat basis, after excluding patients who had primary
amputations. Demographic comparisons were made us-
ing two-tailed Fisher’s exact test for categorical variables
and by t test for continuous variables. Multivariate anal-
ysis using Cox proportional regression was used to iden-
tify the independent predictors of limb loss, patency, and
survival. All P values were considered significant if .05.
Institutional Review Board approval was obtained for the
12 mo 24 mo 36 mo
Non-DM (n=388) 311 206 138
D-OM (n=91) 79 51 34
OM+INS (n=88) 65 41 24
INS (n=125) 76 41 23
Fig 1. Overall survival after revascularization. Non-DM
tion-controlled group; OMINS, oral medication plus
and D-OM groups were each significantly better than Ostudy.RESULTS
There were 746 patients (739 males, 886 limbs), of
whom 406 patients (464 limbs) were in the non-DM
group, 96 patients (135 limbs) in the D-OM group, 98
patients (118 limbs) in the OMINS group, and 146
patients (185 limbs) in the INS group. Demographics,
comorbidities, and presentation modes are shown in Table
I. Patients with DM were more likely to have coronary
artery disease (CAD), hypertension, renal insufficiency, be
on angiotensin-converting enzyme inhibitors (ACEI), and
less likely to be active smokers. The INS group were more
likely to have renal insufficiency and dialysis dependence
than the other groups, whereas patients in OMINS and
INS groups were more likely to be nonambulatory than the
D-OM and non-DM groups. There were more patients
with foot sepsis in the INS group (6%), andmore patients in
the insulin-users group had gangrene, whereas claudication
and rest pain were more common in the non-DM group.
The most distal level of interventions and the type of
interventions are shown in Table II. There were more
patients in the INS group who had infrapopliteal interven-
tions, whereas aortoiliac interventions were more common
o 60 mo
47
15 
1 
10 
P<.001 
diabetic group; D-OM, diet-controlled or oral medica-
n-controlled group; INS, insulin-only group. Non-DM
NS and INS groups (P  .001).48 m
91
24
11
18
, non
insuliin the non-DM group. More patients in the OM-INS or
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jority of endovascular-treated lesions were in the TASC C
and D category in all groups, with marginally higher pro-
portion in patients using insulin (non-DM, 59%; D-OM,
65%; OM-INS, 69%; INS, 74% (P .06). More patients in
the OM-INS or INS groups had primary amputations (9%
in OM-INS and 14% in INS, vs 4% in non-DM and D-OM
groups (P .001). Of the patients who underwent infrain-
guinal bypass procedures (n  243), 46% (n  111) were
performed with autologous vein grafts (66% [n  81] for
infrapopliteal, 45% [n  26] for below-knee popliteal, and
7% [n  4] for above-knee popliteal bypasses).
The 30-day mortality for endovascular-treated patients
was 1.8% for non-DM, 0% for D-OM, 1.2% for OM-INS,
and 3.0% for INS groups (P .968). The 30-day mortality
rate for open treated patients was 3.4% for the whole group,
1.6% for non-DM, 5.8% for D-OM, 3.6% for OM-INS, and
7.0% for the INS groups (P .113). The 30-day mortality
in open-treated non-DM patients was not statistically dif-
ferent than DM groups (1.6% vs 5.8%, P  .1), and the
30-day mortality in diabetic subgroups was also similar
   12 mo 24 mo 36 mo
Non-DM (n=446) 342 213 140 
 
D-OM (n=114) 97 56 36 
 
OM+INS (n=107) 76 39 22 
 
INS (n=158)  66 39 23 
Fig 2. Limb salvage rates in groups after revasculariza
controlled or oral medication-controlled group; OM
insulin-only group. Non-DM and D-OM groups were e
.001); OMINS vs INS, P  .094.(P  .727). The 30-day mortality in the open-treatedINS group was marginally worse than the non-DM
group (1.6% vs 7.0%, P  .06). An additional two
patients in the non-DM group (1.1%), one in the OM-
INS group (3.6%), and one in the INS group (1.8%) who
had open revascularizations had perioperative nonfatal
myocardial infarctions.
Mean follow-up was 26.3 20.7 months. The survival
rates in non-DM and D-OM groups were very similar
(4-year survival 64% 3% vs 70% 6%), and OM-INS and
INS groups were also similar (28%  7% vs 34%  6%);
however, the survival rates in the insulin users were signif-
icantly (P  .001) worse than those who were not on
insulin (Fig 1). When only those with CLI were included,
or when the dialysis patients were excluded, the survival
between the groups also showed the same pattern, with
patients on insulin having significantly lower survival than
those in the non-insulin groups.
The LS rates were almost identical in non-DM and
D-OMgroups (four-year LS rates, 89% 2% vs 93% 3%),
whereas patients in OM-INS (73%  6%) and INS groups
(56% 6%) had significantly worse LS rates than those who
o 60 mo  
46  
16 
5 
1 
P<.001 
rocedures. Non-DM, nondiabetic group; D-OM, diet-
, oral medication plus insulin-controlled group; INS,
gnificantly better than OMINS and INS groups (P  48 m
87 
26 
12 
9 
tion p
INS
ach siwere not insulin users, and there was a trend for the
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groups (P  .094; Fig 2). Similar observations were made
when only CLI patients were compared, with insulin users
having poorer LS than those who were not (P  .001);
however, the difference between the patients in the OM-
INS and INS groups was less pronounced. When dialysis
patients were excluded, similar observations were made,
with the difference between OM-INS and INS being less
pronounced. In CLI patients, LS rates after open revascu-
larizations were worst in insulin users (4-year LS, 56% 
8%), whereas D-OM (88% 6%) and non-DM (75% 5%)
had better LS rates (Fig 3; P  .013). In those who had
endovascular interventions, the LS rates were almost iden-
tical in non-DM and D-OM groups (four-year LS, 92% 
3% vs 87%  8%), whereas those in the OM-INS and INS
groups had significantly worse LS rates (70% 9.8% vs 50%
9%; P  .001; Fig 4). The difference between LS rates in
patients with CLI in the OM-INS and INS groups was signif-
icant (P .042).
The PP following endovascular interventions was sim-
ilar between non-DM and D-OM groups (three-year PP,
72% 4% vs 78% 6%, P .989), which were significantly
better (P  .001) than OM-INS (60%  8%) and INS
    12 mo 24 mo
Non-DM (n=119)  78 53 
 
D-OM (n=24)   19 13 
 
OM+INS and INS (n=77) 40 25 
Fig 3. Limb salvage following open revascularization in
non-diabetic group; D-OM, diet-controlled or oral me
insulin-controlled group; INS, insulin-only group. Non-
.024; non-DM vs OMINS and INS, P  .019.groups (50% 9%; OM-INS vs INS, P .193; Fig 5). Thedifference was still significant when only CLI patients who
had endovascular interventions were compared (two-year
PP, 68%  5% vs 79%  9% vs 55%  6%, non-DM vs
D-OM vs insulin groups, P  .02). The PP was similar in
patients who presented with DC on all groups (P  .510).
The PP was similar following open revascularizations both
in patients who presented with CLI (P  .749) and with
DC (P  .976) for all groups.
The SP rates were significantly worse in the INS group
than all the other groups (Fig 6; P  .005). The SP in
claudicants was similar in endovascular-treated patients
(P  .851). However, SP was significantly better in the
D-OM and OM-INS groups than non-DM and INS
groups in endovascular-treated patients with CLI (P 
.037), suggesting that with repeated interventions, a better
SP could be achieved in these diabetic groups, whereas the
INS group and the non-DM group had worse SP. SP
following open revascularizations was similar among all
groups (P  .3).
In the endovascular-treated patients, 14% had reinter-
ventions (37 endovascular, 1 open) in the diabetic patients
to maintain assisted PP, whereas this was 7% (17 endovas-
cular, 2 open) in the nondiabetic patients (P .024), with
o 48 mo 60 mo  
31 23  
8 7 
9 4 
P=0.013 
nts who presented with critical limb ischemia.Non-DM,
ion-controlled group; OMINS, oral medication plus
s D-OM, P  .244; D-OM vs OMINS and INS, P  36 m
41 
34 
18 
patie
dicat
DM vno difference in the patients with diabetes. Reinterven-
D-OM
JOURNAL OF VASCULAR SURGERY
May 20101184 Dosluoglu et altions after occlusion of the endovascular-treated seg-
ments (thrombolysis with or without mechanical throm-
bectomy, or recanalization of the occluded segment) were
performed in 5% of diabetic patients and 4% of nondiabetic
patients, with no difference between groups. An open
bypass was eventually necessary in 5% of diabetic patients
and 4% of nondiabetic patients, with no difference between
diabetic subgroups. In the open group, 8% of diabetics and
7% of non-diabetics required interventions to maintain
assisted PP, and 8% of the diabetic patients and 12% of the
nondiabetic patients required reinterventions after graft
occlusion, and there were no differences between groups.
Repeat bypass (n  31) and endovascular recanalizations
(n  5) were performed after graft occlusion in 12% of
diabetic patients and 13% of nondiabetic patients, with no
difference between groups.
In multivariate analysis using Cox regression, CAD,
chronic obstructive pulmonary disease, CLI, renal insuffi-
ciency, statin drug nonuse, insulin therapy, and non-
ambulatory status were found to be associated with de-
creased survival (Table III). Limb loss was found to be
12 mo 24 mo 36 mo
Non-DM (n=129) 90 60 30 
 
D-OM (n=41)  34 19 12 
 
OM+INS (n=94) 37 22 13 
 
INS (n=63)  39 14 7 
Fig 4. Limb salvage following endovascular revasculari
Non-DM, nondiabetic group;D-OM, diet-controlled or
plus insulin-controlled group; INS, insulin-only group.
.072; OMINS vs INS, P  .042; INS vs non-DM, orassociated with insulin use, in addition to nonambulatorystatus, infrapopliteal interventions, and the presence of
gangrene (Table IV). Poorer PP was found to be associated
with infrapopliteal interventions, CLI, and the presence of
TASC C or D lesions (Table V). Insulin use, CAD, hyper-
tension, statin use, renal insufficiency, and type of interven-
tions did not correlate with PP.
DISCUSSION
Diabetes remains one of the most important risk factors
of peripheral arterial occlusive disease and is present in 25%
to 75% of all patients presenting with CLI.3,5,15-17 The
relative incidence of DM in our study population (48%) was
well within this range. The optimal management of diabetic
patients is still being defined.11,18,19
Demographics and clinical presentation. In our se-
ries, patients in the INS group were the sickest, with the
highest rate of renal insufficiency, dialysis dependence, and
nonambulatory status, while the OMINS group had
more patients who were nonambulatory than the D-OM
group. All the subgroups in DM group had a higher
incidence of CAD, hypertension, and renal insufficiency,
o   
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Volume 51, Number 5 Dosluoglu et al 1185patients. Patients who were using insulin were more likely
to present with tissue loss, with or without advanced infec-
tion (foot sepsis), with the INS group having the highest
rate. The level of intervention was infrapopliteal, and mul-
tilevel in more patients on insulin, with the INS group
having the highest rate of all groups. All these were re-
flected by the higher primary amputation rates in insulin
users, the highest being in the INS group. These findings all
suggest that dividing the patients based on their insulin
needs allows a reasonable stratification of diabetic patients
when the comorbidities, presentation, and the types of
intervention are considered.
Survival. The overall mortality of diabetic patients
with chronic limb ischemia in previous reports has ranged
from 30% at 1 year13 to only 42% at 5 years.10 Patients
who received insulin for diabetes were also shown to
have an increased rate of cardiovascular events and mor-
tality.19,20 In our study, insulin use was found to be inde-
pendently associated with decreased survival, with the sur-
vival of noninsulin-dependent diabetic patients identical to
nondiabetics (50%-70% at five years), and survival in the
   12 mo 24 mo 36 mo
Non-DM (n=267) 167 91 54 
 
D-OM (n=80)  56 26 18 
 
OM+INS (n=79) 40 18 9 
 
INS (n=101)  31 11 5 
Fig 5. Primary patency following endovascular reva
controlled or oral medication-controlled group; OM
insulin-only group. Non-DM vs INS, P .001; D-OM v
OMINS, P  .068.insulin subgroups was also very similar (17%-28% at fiveyears); both significantly less than the non-insulin users. We
found similar results when we compared only those who
presented with CLI.
Limb salvage. The effect of diabetes on limb salvage
rates has been conflicting, regardless of the revasculariza-
tion technique employed. DeRubertis et al12 reported 88%
one-year LS rates in patients with or without DM following
percutaneous interventions, and although the PP rate was
less in the DM group, they concluded that this was likely
due to having a higher proportion of CLI in diabetic
patients, and, with repeated interventions, similar patency
and limb salvage rates were achieved. In contrast, Bakken et
al11 found significantly lower LS rates in diabetics (one-year
LS rate was 67% in noninsulin-dependent diabetics and
73% in insulin-dependent diabetics, whereas it was 89% in
nondiabetics) who had SFA endovascular interventions
with no difference in patency. Other series have reported
75% to 91% LS rates one year following endovascular
interventions.13,18,26-28 Dick et al13 reported that patients
with DM had similar LS at one year with nondiabetics, and
whether the initial treatment was open or endovascular did
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May 20101186 Dosluoglu et albypasses, some reports suggested similar LS rates following
bypass procedures,3,7,10 whereas others noted lower LS
rates.29,30 Akbari et al10 reported a five-year LS rate of 87%
following infrainguinal vein bypasses, with a five-year sur-
vival rate of 58%, both similar to their nondiabetic patients.
In our study, patients in the D-OM group had identical LS
rates with nondiabetics, both of which were significantly
better than the insulin users. This was similar when only
CLI patients were included, and the OMINS group had
slightly better LS rates than the INS group, but this did not
reach statistical significance. The LS rates in the insulin
groups were worse than in the noninsulin users both in the
open and endovascular-treated patients with CLI; however,
the difference between the OMINS and INS groups was
also different in endovascular-treated patients. Of note, the
LS rate in our D-OM group (four-year LS 87% for endo-
vascular, 88% for open groups) was close to that reported
by Akbari et al,10 although their series included only pa-
tients with autologous vein reconstructions.
Patency. Patency rates have also been reported to differ
in diabetics following endovascular and open reconstruc-
   12 mo 24 mo 36 mo
Non-DM (n=267) 182 107 63 
 
D-OM (n=80)  59 30 20 
 
OM+INS (n=79) 52 27 16 
 
INS (n=101)  37 16 7 
Fig 6. Secondary patency following endovascular rev
controlled or oral medication-controlled group; OM
insulin-only group. Non-DM vs INS, P  .007; D-OM
D-OM or OMINS, P  NS.tions, based on the indication for intervention. Bakken etal11 found that the insulin-dependent diabetics had
worse PP and APP than nondiabetics and noninsulin-
dependent diabetics following percutaneous SFA interven-
tions for claudication but similar patency rates to CLI
patients. Others12,13 have reported that diabetic patients
with CLI have higher restenosis and reintervention rates,
but comparable limb salvage rates can be achieved. We
found similar PP rates in the diabetic subgroups following
both endovascular and open procedures in claudicants and
those with CLI who underwent open bypasses. However,
PP was different in patients who presented with CLI and
had endovascular interventions, with insulin users having
the worst outcomes. The SP rates were also worse in the
endovascular-treated patients on insulin with CLI. Multi-
variate analysis showed that CLI, TASC classification C or
D, and need for infrapopliteal interventions were associated
with worse patency rates, whereas insulin use and the type
of procedure were not. Our poorer results in insulin users
may be a reflection that patients who are on insulin had
more complex anatomy and worse clinical presentation.
The effect of hyperglycemia, insulin resistance, andDM
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and increases endothelium-derived NO synthase expres-
sion,33 while glucose inhibits the production of NO34
along with prostaglangin I2.
35 Elevated glucose and insulin
levels are associated with an increased secretion of the
vasoconstrictor, endothelin-1, and impaired glucose toler-
ance increases arterial stiffness.36 Serum insulin and C-
peptide levels have been suggested to be associated with
restenosis following percutaneous angioplasties in claudi-
cants and CLI patients.37 Although it is not clear if the
effects of insulin are primarily correlated with worsening of
atherosclerotic disease or if it is simply a marker of more
severe disease21,22 and how much of its glycemic control
counteracts its direct effects on the vascular system, our
results suggest that subdividing the diabetic patients into
groups based on their insulin need is reasonable and allows
better stratification of patients.
The main weakness of our study is the retrospective
nature and lack of randomization. It is almost exclusively
composed of men, and our findings may not be applicable
Table III. Multivariate analysis (Cox regression) for
survival
Hazard
ratio
95% Confidence
interval P
Coronary artery disease 1.8 1.4-2.4 .001
Chronic obstructive
occlusive disease 1.5 1.2-1.9 .002
Renal 1.9 1.4-2.4 .001
Statin nonuse 1.4 1.1-1.8 .004
Indication 2.3 1.6-3.3 .001
Insulin 1.5 1.1-1.9 .003
Nonambulatory 1.9 1.5-2.5 .001
Table IV. Multivariate analysis (Cox regression) for limb
salvage
Hazard
ratio
95% Confidence
interval P
Insulin 2.4 1.5-3.6 .001
Nonambulatory 1.9 1.3-2.9 .002
Infrapopliteal 3.3 2.2-5.2 .001
Gangrene 2.3 1.3-2.9 .001
Table V. Multivariate analysis (Cox regression) for
primary patency
Hazard
ratio
95% Confidence
interval P
Infrapopliteal 1.8 1.4-1.9 .001
DC/CLI 1.5 1.1-2.1 .021
TASC C/D 2.1 1.3-3.3 .002
CLI,Critical limb ischemia;DC, disabling claudication;TASC,TransAtlantic
Society Consensus.to female patients. All the patients were subgrouped fortheir medication status at the time of presentation. Thus,
patients crossing over to other groups during the study
would not have been identified during follow-up. We also
did not document the duration of DM, monitor the com-
pliance of the patients with glucose control, and did not
monitor HbA1c levels.
CONCLUSIONS
Diabetic patients who present with limb ischemia can
be divided into three distinct subgroups based on their
diabetic regimen, with different presentation and treatment
modes, and LS and survival. The survival and LS rates of
those controlled with diet or OM are nearly identical to
nondiabetics. The PP rate in EV-treated patients is worse in
patients who are on insulin. Insulin usage is independently
associated with decreased survival and limb loss but not
patency. Studies comparing DM with non-DM should
definitely specify insulin use, with or without combination
with oral medications.
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Dr Theodore Teruya (Loma Linda, Calif). The authors
found that patients who use insulin as either monotherapy or in
combination with oral hypoglycemic agents had worse limb sal-
vage and survival.
It is well known that tight glycemic control can limit the
complications of diabetes. Did the authors measure hemoglobin
A1c levels and, if so, were they significantly different in the groups
with diabetes? Was the use of insulin just a marker of poor glycemic
control?
We also know that the most frequent cause of limb loss in
diabetics is due to pedal sepsis and not critical limb ischemia. How
many patients suffered limb loss due to overwhelming infections orscript here at this meeting in 2002 that showed that 24% of major
amputations performed were from pedal sepsis or extensive tissue
loss.
Finally, what was the rationale for including patients without
critical limb ischemia (ie, the claudication group) in this study?
There were more claudicants in the nondiabetic and oral hypogly-
cemic agent groups, than in the groups that took insulin. Do you
think this affected the outcome of the study?
Dr Dosluoglu. This is a retrospective study, and that’s the
weakness of the study. I tried to see if the patients did have data on
hemoglobin A1c levels. It was really not very reliably found. So I’m
not going to be able to give you any data on the tight control vs
long-term or short-term on this subgroup, but I agree with you.
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 5 Dosluoglu et al 1189Another aspect of this is that hemoglobin A1c actually could
be a reflection of other end products of poor diabetes control as
well, so we are planning on prospectively evaluating this in the
future. I truly believe though this may be not only tight control,
but it is a reflection of the level of diabetes affecting the outcomes.
As to the last question, we did include the diabetics and
claudicants to see if there were patency differences, as was sug-
gested by the University of Rochester paper. I actually analyzed
them separately so that we could actually iron that out in terms of
outcomes.
Lastly, the infection-related amputations were clearly more
common in the insulin group than others. I looked at it also; it was
about 50% of the patients who had infection-related amputation.
We just recently wrote a paper, which was published in the June
issue of the Journal, on the limb loss with patent endovascular-treated segments, in which we observed that a lot of the amputa-
tions occurred in patients with patent stents, which is a reflection of
our aggressiveness in that we try to save these limbs, and we lose
some due to infections. It may be related to poor glucose control,
but I do not have the specific data for that.
Dr Jonathan Eliason (Ann Arbor, Mich). Was there any
consideration to look at the type of insulin control that patients
had: long-acting, sliding-scale–based, older formulations, or
newer formulations, and whether or not there is a difference? I
know it’s tough to tease those out.
Dr Dosluoglu. It could be done. That’s easier than getting
the hemoglobin A1c, because hemoglobin A1c was not necessarily
obtained in a lot of these, so I cannot really get that. Due to the
large number of patients, this would require a lot of effort, and we
elected not to do that for this study.
